Figure 1.
Figure 1.

Flow chart outlining the timeline of study events after a 7 d acclimatization period, lameness induction with 15 mg of amphotericin B, and oral treatment with a placebo (PLBO) or meloxicam (MEL) at 0.5 mg/kg alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d.

 


Figure 2.
Figure 2.

Mean ± SE for plasma meloxicam (MEL) concentrations after oral treatment with 0.5 mg/kg MEL once daily for 4 d (arrows) following lameness induction with amphotericin B at 6 h before first treatment.

 


Figure 3.
Figure 3.

Mean ± SE for plasma meloxicam (MEL) and gabapentin (GABA) concentrations after oral treatment with 0.5 mg/kg MEL alone or in combination with 15 mg/kg GABA once daily for 4 d (arrows) following lameness induction with amphotericin B at 6 h before first treatment.

 


Figure 4.
Figure 4.

Mean ± SE lameness scores after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05. Lameness Score (LS); 0 = normal: stands and walks normally, with all feet placed with purpose; LS 1 = mildly lame: stands with flat back but arches when walks; gait is slightly abnormal; LS 2 = moderately lame: stands and walks with an arched back and short strides with 1 or more legs; LS 3 = lame: arched back standing and walking, with 1 or more limbs favored but at least partially weight bearing; and LS 4 = severely lame: arched back, refuses to bear weight on 1 limb, or may refuse or have great difficulty moving from lying position

 


Figure 5.
Figure 5.

Distribution of lameness scores after oral treatment with a lactose monohydrate placebo (PLBO; n = 6; panel a), 0.5 mg/kg of meloxicam (MEL; n = 6; panel b), or 0.5 mg/kg of MEL combined with 15 mg/kg gabapentin (MEL-GABA; n = 6; panel c) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. Lameness scores (LS) were assigned according to the following system; LS0 = normal: stands and walks normally, with all feet placed with purpose; LS 1 = mildly lame: stands with flat back but arches when walks; gait is slightly abnormal; LS 2 = moderately lame: stands and walks with an arched back and short strides with 1 or more legs; LS 3 = lame: arched back standing and walking, with 1 or more limbs favored but at least partially weight bearing; and LS 4 = severely lame: arched back, refuses to bear weight on 1 limb, or may refuse or have great difficulty moving from lying position

 


Figure 6.
Figure 6.

Mean ± SE serum cortisol concentrations after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05). Lameness Score (LS); 0 = normal: stands and walks normally, with all feet placed with purpose; LS 1 = mildly lame: stands with flat back but arches when walks; gait is slightly abnormal; LS 2 = moderately lame: stands and walks with an arched back and short strides with 1 or more legs; LS 3 = lame: arched back standing and walking, with 1 or more limbs favored but at least partially weight bearing; and LS 4 = severely lame: arched back, refuses to bear weight on 1 limb, or may refuse or have great difficulty moving from lying position

 


Figure 7.
Figure 7.

Mean ± SE step count assessed with pedometer after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05). Lameness Score (LS); 0 = normal: stands and walks normally, with all feet placed with purpose; LS 1 = mildly lame: stands with flat back but arches when walks; gait is slightly abnormal; LS 2 = moderately lame: stands and walks with an arched back and short strides with 1 or more legs; LS 3 = lame: arched back standing and walking, with 1 or more limbs favored but at least partially weight bearing; and LS 4 = severely lame: arched back, refuses to bear weight on 1 limb, or may refuse or have great difficulty moving from lying position

 


Figure 8.
Figure 8.

Mean ± SE percent force distributed to the lateral claw after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05).

 


Figure 9.
Figure 9.

Mean ± SE percent force distributed to the medial claw after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05).

 


Figure 10.
Figure 10.

Mean ± SE ADG in body weight (kg) after oral treatment with a placebo (PLBO) or 0.5 mg/kg meloxicam (MEL) alone or in combination with 15 mg/kg gabapentin (MEL-GABA) once daily for 4 d following lameness induction with amphotericin B at 6 h before first treatment. a,bTime points not connected by the same letter are significantly different (P < 0.05).